Diagnostics has not been a field of interest for venture capitalists - the margins have been too low. Mindsense Biosystems Ltd. believes it can do better.

"We know the diagnostics field is quite boring, business-wise, but it's boring for good reasons," said CEO Nir Nimrodi. "Much of the innovation is just improved automation or performance. But new biomarkers, such as PSA for prostate cancer, or Chiron Corp.'s hepatitis B and C antigens - these were not boring."